{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[14,2,14,3],[15,2,15,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910495243103321"]
[null,null,"Titolo",null,"Identification of biomarkers, new treatments, and vaccines for COVID-19 / / Paul C. Guest, editor"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2021]"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"3-030-71697-X"]
[null,null,"Descrizione fisica",null,"1 online resource (229 pages)"]
[null,null,"Collana",null,"Advances in experimental medicine and biology ; ; 1327"]
[null,null,"Disciplina",null,"614.592414"]
[null,null,"Soggetti",null,"COVID-19 (Disease)"]
[{"$nulls":4},"COVID-19"]
[{"$nulls":4},"Marcadors bioquímics"]
[{"$nulls":4},"Terapèutica"]
[{"$nulls":4},"Vacunes"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Contents -- Part I: Background -- 1: Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement -- 1  Introduction -- 2  Epidemiology -- 3  Main Coronavirus Groups -- 4  Genome, Genotype, and Protein Structure -- 5  Mechanism of Infection -- 6  COVID-19 Pathogenesis -- 7  Respiratory Manifestations -- 8  Extra-pulmonary Presentations -- 8.1  Gastrointestinal Manifestations -- 8.2  Cardiovascular Complications -- 8.3  Haematological Disorders -- 9  Immune Responses -- 10  Therapy -- 10.1  Drugs that Slow Viral Replication or Kill SARS-Cov-2 -- 10.2  Vaccination -- 11  Conclusion -- References -- Part II: Epidemiology -- 2: Prevalence of COVID-19 and the Continued Citizen-Based Control in Japan -- 1  Introduction -- 2  Cruise Ship Outbreak and the Environmental Assessment -- 2.1  COVID-19 Outbreak on the Diamond Princess Cruise Ship -- 2.2  Age-Related CFR Estimated from the Cruise Ship Outbreak -- 2.3  Environmental Assessment of SARS-CoV-2 on the Cruise Ship -- 3  Government-Recommended and Voluntary Measures to Protect Against COVID-19 Infection in Japan -- 4  Detection of the Coronavirus in Laboratories in Japan -- 5  Conclusions -- References -- 3: COVID-19 Pandemic in Brazil: History, Characteristics, and Evolution -- 1  Brief Historical "]
[{"$nulls":4},"Facts of the COVID-19 Pandemic in Brazil -- 2  Governmental Measures to Combat the Pandemic -- 3  Regional Characteristics Influencing the COVID-19 Dissemination -- 4  Prevalence of the Disease in Different Subpopulations -- 5  Concluding Remarks -- References -- 4: The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study -- 1  Introduction -- 2  Methods -- 2.1  Data Collection -- 2.2  Data Analysis -- 3  Results -- 3.1  Theme I: Emotional-Sensational-Paradox -- Satisfaction-Dissatisfaction -- Positive Experiences-Negative Experiences."]
[{"$nulls":4},"Relaxation-Stress -- Support-Rejection -- 3.2  Theme II: Spiritual Growth -- Accepting and Submitting to Divine Providence -- Rethinking Material Possessions -- Seeking Stronger Divine Connection -- Tendency to Spirituality -- 3.3  Theme III: Experienced Mental-Psychological Effects -- Unpleasant Thoughts -- Perceived Mental Stress -- Positive Thoughts -- 4  Discussion -- 5  Conclusions -- References -- Part III: Risk Factors and Outcomes -- 5: Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons -- 1  Introduction -- 2  Age-Related Effects of Different Infections -- 3  Age Effects of COVID-19 Disease -- 4  Clinical Features in Children -- 5  The Different Etiology and Severity of COVID-19 Based on Age -- 6  Underlying Conditions and Severity of COVID-19 in Children -- 7  Outdoor Activities and the Potential to Contract the Virus -- 8  Immune System and Age-Related Differences -- 9  Innate Immune Cells and Age-Related Differences -- 10  IFN-γ and SARS-CoV in Children -- 11  Adaptive Immune Response and Age-Related Difference -- 12  Cross-Protection Against SARS-CoV-2 and Age-Related Differences -- 13  Improved Efferocytosis by Bacillus Calmette-Guerin (BCG) Vaccine to Protect Against COVID-19 Pneumonia -- 14  Age-Related Difference and Higher Hemoglobin in COVID-19 Pneumonia -- 15  The Role of Sex Hormones and Age-Related Differences in COVID-19 -- 16  Interferon as a Target Therapy in Coronavirus Disease 2019 (COVID-19) -- 17  The Role of Lactoferrin in Immune System Age-Related Differences -- 18  The Recommendations for Selecting Treatment in Patients Based on Age and Neutrophil-to-Lymphocyte Ratio (NLR) -- 19  Conclusions -- References -- 6: Sex Differences and COVID-19 -- 1  Introduction -- 1.1  COVID-19 -- 1.2  Sex and the COVID-19 Response."]
[{"$nulls":4},"2  Physiological Sex Differences as Potential Moderators of COVID-19 Outcomes -- 2.1  The Immune System and COVID-19 -- 2.2  Sex Differences in the Immune System -- 2.3  Sex Hormones and the Immune Response -- 2.4  Sex Hormones and COVID-19 -- 2.5  Sex Chromosomes and the Immune System -- 2.6  Ageing, Sex and the Immune System -- 3  Sex Differences in the Renin-Angiotensin-Aldosterone System -- 3.1  Sex Differences in the Renin-Angiotensin System and COVID-19 -- 4  Reproduction, Pregnancy and COVID-19 -- 5  Long-Term Outcomes of COVID-19 and Sex Differences -- 6  Conclusion and Perspectives -- References -- 7: Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? -- 1  Introduction -- 1.1  Epidemiological Characteristics of Coronavirus Diseases -- 1.2  Coronavirus Disease 2019 (COVID-19) -- 2  Microbiota and Respiratory Infection -- 3  Potential Connections Between Intestinal Microbiota and COVID-19 -- 3.1  Age Effects -- 3.2  Hypertension -- 3.3  Diabetes -- 3.4  Obesity -- 4  COVID-19 and Microbiota -- 5  Conclusions and Future Perspectives -- References -- 8: SARS-CoV-2 Infection and the Kidneys: An Evolving Picture -- 1  Introduction -- 2  Dialysis -- 3  Transplant -- 4  Chronic Kidney Disease -- 5  Apo L1 -- 6  The Clinical Picture of Kidney Disease in COVID-19 -- 6.1  Acute Kidney Injury Pathophysiology -- 7  "]
[{"$nulls":4},"Conclusions -- References -- 9: Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information -- 1  Introduction -- 2  Exanthem Pattern -- 2.1  Vesicular Eruptions or Varicella-Like Exanthem -- 2.2  Maculopapular Eruptions or Maculopapular Rash -- 3  Urticarial Lesions -- 4  Vascular Pattern -- 4.1  Acral Areas of Erythema with Vesicles or Pustules (Pseudo-Chilblain) -- 4.2  Purpuric/Petechial Lesions -- 4.3  Livedo or Necrosis -- 5  Acro-Papular Eruption -- 6  Treatment -- 7  Pathophysiological Mechanisms."]
[{"$nulls":4},"8  Conclusions -- References -- 10: How Do We Manage Breastfeeding During the COVID-19 Pandemic? -- 1  Introduction -- 2  Benefits of Breastfeeding -- 3  COVID-19 and Breastfeeding: Current Evidence -- 4  Guidelines on Breastfeeding for Mothers with Suspected or Confirmed COVID-19 -- 5  Conditions Recommended for Starting and Maintaining Breastfeeding -- 6  Conditions in Which It Is Recommended to Extract Breast Milk -- 7  Conditions in Which Recommended for Not Breastfeeding or Extracting Breast Milk -- 8  Breastfeeding by Mothers Undergoing Medications for COVID-19 -- 9  Conclusions and Future Perspectives -- References -- 11: Deep Learning Analysis in Prediction of COVID-19 Infection Status Using Chest CT Scan Features -- 1  Introduction -- 2  Methods -- 2.1  Study Design and Participants -- 2.2  CT Examination and Image Analysis -- 2.3  Statistical Analysis -- Comparisons Between Two Groups -- Deep Learning Analyzing and Classification -- 3  Results -- 3.1  Demographic Characteristics and Chest CT Findings -- 3.2  Deep Learning Analyzing Results -- 4  Discussion -- 5  Conclusions -- References -- Part IV: Treatments and Vaccines -- 12: Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review -- 1  Introduction -- 2  Methods -- 2.1  Inclusion Criteria -- 2.2  Search Strategy -- 3  Results -- 3.1  Extraction of Results -- 3.2  Protocols -- 3.3  Mechanism of Ozone as a Treatment -- 3.4  Ozone Therapy and Viral Infections -- 3.5  Ozone Therapy and Respiratory System -- Asthma -- Chronic Obstructive Pulmonary Disease (COPD) -- Pulmonary Emphysema -- 4  Discussion -- 5  Conclusions and Future Perspective -- References -- 13: COVID-19, Coenzyme Q10 and Selenium -- 1  Introduction -- 2  CoQ10 -- 3  Selenium -- 4  Oxidative Stress, Inflammation and Virus Infection -- 4.1  Oxidative Stress -- 4.2  Inflammation."]
[{"$nulls":4},"5  Supplementation CoQ10 and Selenium -- 6  Conclusions and Future Perspectives -- References -- 14: Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19) -- 1  Introduction -- 2  Agents with Known Effect Against SARS-CoV-2 -- 2.1  Alcohol and Isopropanol -- 2.2  Povidone-Iodine -- 2.3  Hydrogen Peroxide -- 2.4  Ultraviolet (UV) Radiation -- 2.5  Xylitol -- 2.6  Brilacidin -- 2.7  Carrageenan -- 3  Agents with Potential Effect on SARS-CoV-2 -- 3.1  Acid-Buffered Saline -- 3.2  Hypertonic Saline -- 3.3  Oxymetazoline and Xylometazoline -- 3.4  Probiotics -- 3.5  Chlorhexidine -- 3.6  Citrox (Flavonoids) and Cyclodextrins -- 3.7  Cetylpyridinium Chloride (CPC) -- 3.8  Surfactants/Shampoo -- 3.9  Interferon -- 4  Therapeutic Application and Method of Delivery -- 5  Conclusions -- References -- 15: Cinnamon: A Promising Natural Product Against COVID-19 -- 1  Introduction -- 2  Antiallergic Properties -- 3  Antiviral Properties -- 4  Cardiovascular Properties -- 5  Safety of Cinnamon -- 6  Conclusions and Future Perspectives -- References -- 16: Curcumin and Piperine in COVID-19: A Promising Duo to the Rescue? -- 1  Introduction -- 2  Curcumin-Piperine -- 3  Curcumin-Piperine and Virus-Induced Lung Injury -- 4  Curcumin-Piperine and Thrombosis -- 5  Safety of Curcumin-Piperine -- 6  Conclusions and Future Perspectives -- References -- 17: Association of In-hospital Use of Statins, Aspirin, "]
[{"$nulls":4},"and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19 -- 1  Introduction -- 2  Methods -- 2.1  Study Design and Participants -- 2.2  Data Collection -- 2.3  Medication -- 2.4  Outcomes -- 2.5  Statistical Analysis -- 3  Results -- 4  Discussion -- 5  Conclusion -- References -- 18: The Worldwide Effort to Develop Vaccines for COVID-19 -- 1  Introduction -- 2  The SARS-CoV-2 Spike Protein."]
[{"$nulls":4},"3  SARS-CoV-2 Vaccine Candidates in Phase 3 Clinical Trials."]